Immunologic Research

, Volume 8, Issue 4, pp 305–315 | Cite as

Regulation of C5 convertase activity by properdin, factors B and H

  • John M. Weiler


Classical Pathway Terminal Component Decyl Sulfate Classical Pathway Activity Amplification Pathway 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Daha, M.R.; Fearon, D.T.; Austen, K.F.: C3 requirements for formation of alternative pathway C5 convertase. J. Immun.117: 630 (1976).PubMedGoogle Scholar
  2. 2.
    Weiler, J.M.; Yurt, R.W.; Fearon, D.T.; Austen, K.F.: Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin. J. exp. Med.147: 409 (1978).PubMedCrossRefGoogle Scholar
  3. 3.
    Weiler, J.M.: Polyions regulate the alternativeamplification pathway of complement. Immunopharmacology6: 245 (1983).PubMedCrossRefGoogle Scholar
  4. 4.
    Sharath, M.D.; Merchant, Z.M.; Kim, Y.S.; Rice, K.G.; Linhardt, R.J.; Weiler, J.M.: Small heparin fragments regulate the amplification pathway of complement. Immunopharmacology9: 73 (1985).PubMedCrossRefGoogle Scholar
  5. 5.
    Weiler, J.M.; Gleich, G.J.: Eosinophil granule major basic protein regulates generation of classical and alternative-amplification pathway C3 convertases in vitro. J. Immun.40: 1605 (1988).Google Scholar
  6. 6.
    Weiler, J.M.; Linhardt, R.J.: Comparison of the activity of polyanions and polycations on the classical and alternative pathways of complement. Immunopharmacology (in press).Google Scholar
  7. 7.
    Fearon, D.T.; Austen, K.F.: Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J. exp. Med.142: 856 (1975).PubMedCrossRefGoogle Scholar
  8. 8.
    Vogt, W.; Schmidt, G.; Von Buttlar, B.; Dieminger, L.: A new function of the activated third component of complement: binding to C5, an essential step for C5 activation. Immunology34: 29 (1978).PubMedGoogle Scholar
  9. 9.
    Whaley, K.; Ferguson, A.: Molecular aspects of complement activation. Mol. Aspects Med.4: 209 (1981).CrossRefGoogle Scholar
  10. 10.
    Tack, B.F.; Prahl, J.W.: Third component of human complement: purification from plasma and physicochemical characterization. Biochemistry15: 4513 (1976).PubMedCrossRefGoogle Scholar
  11. 11.
    Fearon, D.T.; Austen, K.F.: Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc. natn. Acad. Sci. USA74: 1683 (1977).CrossRefGoogle Scholar
  12. 12.
    Hunsicker, L.G.; Ruddy, S.; Austen, K.F.: Alternative complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3). J. Immun.110: 128 (1973).PubMedGoogle Scholar
  13. 13.
    Weiler, J.M.; Daha, M.R.; Austen, K.F.; Fearon, D.T.: Control of the amplification convertase of complement by the plasma protein β1H. Proc. natn. Acad. Sci. USA73: 3268 (1976).CrossRefGoogle Scholar
  14. 14.
    Harrison, R.A.; Lachmann, P.J.: Complement technology; in Weir, Handbook of experimental immunology, chapter 39 (Blackwell Scientific Publications, London 1986).Google Scholar
  15. 15.
    Kabat, E.A.; Mayer, M.M.: Experimental immunochemistry (Thomas, Springfield 1961).Google Scholar
  16. 16.
    Caughman, G.B.; Boackle, R.J.; Vesely, J.: A postulated mechanism for heparin's potentiation of C1 inhibitor function. Molec. Immunol.19: 287 (1982).CrossRefGoogle Scholar
  17. 17.
    Raepple, E.; Hill, H.-U.; Loos, M.: Mode of interaction of different polyanions with the first (C1,\(\overline {C1} \)), the second (C2) and the fourth (C4) component of complement. I. Effect on fluid phase\(\overline {C1} \) and on\(\overline {C1} \) bound to EA or to EAC4. Immunochemistry13: 251 (1976).PubMedCrossRefGoogle Scholar
  18. 18.
    Loos, M.; Volanakis, J.E.; Stroud, R.M.: Mode of interaction of different polyanions with the first (C1,\(\overline {C1} \)), the second (C2) and the fourth (C4) component of complement. II. Effect of polyanions on the binding of C2 to EAC4b. Immunochemistry13: 257 (1976).PubMedCrossRefGoogle Scholar
  19. 19.
    Loos, M.; Volanakis, J.E.; Stroud, R.M.: Mode of interaction of different polyanions with the first (C1,\(\overline {C1} \)), the second (C2) and the fourth (C4) component of complement. III. Inhibition of C4 and C2 binding site(s) on\(C1\bar s\) by polyanions. Immunochemistry13: 789 (1976).PubMedCrossRefGoogle Scholar
  20. 20.
    Baker, P.J.; Lint, T.F.; McLeod, B.C.; Behrends, C.L.; Gewurz, H.: Studies on the inhibition of\(C\overline {56} - induced\) lysis (reactive lysis). VI. Modulation of\(C\overline {56} - induced\) lysis by polyanions and polycations. J. Immun.114: 554 (1975).PubMedGoogle Scholar
  21. 21.
    DiScipio, R.G.: The binding of human complement proteins C5, factor B, β1H and properdin to 0 complement fragment C3b on zymosan. Biochem. J.199: 485 (1981).PubMedGoogle Scholar
  22. 22.
    Lambris, J.D.; Alsenz, J.; Schulz, T.F.; Dierich, M.P.: Mapping of the properdin-binding site in the third component of complement. Biochem. J.217: 323 (1984).PubMedGoogle Scholar
  23. 23.
    Daoudaki, M.E.; Becherer, J.D.; Lambris, J.D.: A 34-amino acid peptide of the third component of complement mediates properdin binding. J. Immun.140: 1577 (1988).PubMedGoogle Scholar
  24. 24.
    Takata, Y.; Kinoshita, T.; Kozono, H.; Takeda, J.; Tanaka, E.; Hong, K.; Inoue, K.: Covalent association of C3b with C4b within C5 convertase of the classical complement pathway. J. exp. Med.165: 1494 (1987).PubMedCrossRefGoogle Scholar
  25. 25.
    Weiler, J.M.; Gellhaus, M.A.; Carter, J.G.; Meng, R.L.; Benson, P.M.; Hottel, R.A.; Schillig, K.B.; Vegh, A.B.; Clarke, W.R.; A prospective study of the risk of an immediate adverse reaction to protamine sulfate during cardiopulmonary bypass surgery. (submitted).Google Scholar

Copyright information

© Humana Press Inc. 1989

Authors and Affiliations

  • John M. Weiler
    • 1
    • 2
  1. 1.University of IowaIowa City Veterans Administration Medical Center and Department of Internal MedicineIowa CityUSA
  2. 2.Department of Internal Medicine, SW34E University HospitalUniversity of IowaIowa City(USA)

Personalised recommendations